Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (20)

2024

  1. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  2. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. An Integrated CT and MRI Imaging Model to Differentiate between Adrenal Adenomas and Pheochromocytomas

    Cancers, Vol. 15, Núm. 14

  2. Differences in intraoperative and surgical outcomes between normotensive pheochromocytomas and sympathetic paragangliomas (PPGLs) and hypertensive PPGLs: results from the PHEO-RISK STUDY

    Journal of Endocrinological Investigation, Vol. 46, Núm. 4, pp. 805-814

  3. Genetic Study in Pheochromocytoma: Is It Possible to Stratify the Risk of Hereditary Pheochromocytoma?

    Neuroendocrinology, Vol. 113, Núm. 6, pp. 657-666

  4. Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas

    Frontiers in Endocrinology, Vol. 14

  5. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study

    Endocrine, Vol. 75, Núm. 2, pp. 525-536

  2. Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas

    Endocrine-related cancer, Vol. 29, Núm. 12, pp. 645-655

  3. Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours

    Scientific reports, Vol. 12, Núm. 1, pp. 2671

2020

  1. Lat-1 and glut-1 carrier expression and its prognostic value in gastroenteropancreatic neuroendocrine tumors

    Cancers, Vol. 12, Núm. 10, pp. 1-18

2019

  1. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 5, pp. 320-329

2018

  1. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Prevalence of acromegaly in patients with symptoms of sleep apnea

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408

2015

  1. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments

    European Journal of Endocrinology, Vol. 172, Núm. 2, pp. 115-122

2011

  1. Estudio OASIS: Manejo terapéutico de la acromegalia en un escenario de práctica clínica habitual. Evaluación de la eficacia de las diversas estrategias de tratamiento aplicadas

    Endocrinologia y Nutricion, Vol. 58, Núm. 9, pp. 478-486

2010

  1. Tumores neuroendocrinos

    Endocrinologia y Nutricion, Vol. 57, Núm. SUPPL. 1, pp. 24-29

2001

  1. Severe respiratory failure secondary to Cushing's myopathy

    Journal of Endocrinological Investigation, Vol. 24, Núm. 8, pp. 618-621

1993

  1. Anterior pituitary function after adrenalectomy in patients with Cushing's syndrome

    Postgraduate Medical Journal, Vol. 69, Núm. 813, pp. 547-551